Investigational drug · Phase 3
Sugemalimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NSCLC (Non-small Cell Lung Cancer), Extranodal NK/T-cell Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
17
Any phase or sponsor naming "Sugemalimab"
First trial start
2024
Nov 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sugemalimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC (Non-small Cell Lung Cancer)
- Extranodal NK/T-cell Lymphoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Sugemalimab" as an intervention, largest first.
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCPivotal-lookingRecruiting
AkesoIndustry
NCT06617416 · 560 participants (planned) · Start Nov 12, 2024 · Primary completion Oct 28, 2026
Drug: Cadonilimab (AK104); Sugemalimab · For: NSCLC (Non-small Cell Lung Cancer)
Sites: Jinan, China
- Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05623267 · 346 participants (planned) · Start Jul 1, 2023 · Primary completion Dec 31, 2025
Drug: Sugemalimab; Placebo · For: Limited Stage Small Cell Lung Cancer
Sites: Guangzhou, China
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized TrialPivotal-lookingNot yet recruiting
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07190027 · 246 participants (planned) · Start Nov 2025 · Primary completion Nov 2025
Drug: Arm 1: Standard Synchronous Group; Arm 2:Fixed Delay Group and 1 more · For: Advanced Non-Small Cell Lung Cancer (NSCLC)
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaPivotal-lookingNot yet recruiting
CStone PharmaceuticalsIndustry
NCT05700448 · 150 participants (planned) · Start Jun 2027 · Primary completion Dec 2029
Drug: Sugemalimab; Placebo and 3 more · For: Extranodal NK/T-cell Lymphoma
Peking Union Medical CollegeAcademic, hospital or other
NCT07247227 · 150 participants (planned) · Start Oct 10, 2023 · Primary completion May 2027
Drug: Sugemalimab and Chemotherapy · For: NSCLC
Sites: Beijing, China
- Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCCActive, not recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07711470 · 140 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2028
Drug: Sugemalimab and Chemotherapy; Nab-paclitaxel and 1 more · For: Esophageal Squamous Cell Carcinoma (ESCC)
Sites: Beijing, China
- Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyPivotal-lookingStatus unknown
Zhejiang Cancer HospitalAcademic, hospital or other
NCT06031597 · 105 participants (planned) · Start Sep 15, 2023 · Primary completion Dec 31, 2025
Drug: Platinum-Based Drug; Immunotherapy and 1 more · For: Non-small Cell Lung Cancer Stage III
Second Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT04770207 · 100 participants (planned) · Start Nov 1, 2020 · Primary completion Nov 1, 2029
Drug: Injection of drug-eluting microspheres with multiple drugs into solid tumors · For: Hepatocellular Carcinoma; Solid Tumor, Adult
Sites: Guangzhou, China
- Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative DeliriumCompleted
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT05273827 · 81 participants · Start Mar 22, 2022 · Primary completion Dec 20, 2023
Drug: neoadjuvant immunotherapy; Neoadjuvant chemotherapy · For: Immunotherapy; Analgesia; NSCLC and 1 more
Sites: Tianjin, China · 3 sites in all
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT06869239 · 65 participants (planned) · Start Feb 25, 2025 · Primary completion Jan 3, 2027
Drug: Etoposide + cisplatin/carboplatin; PD-L1 inhibitor · For: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.
Yan C, He J, Lv G, et al. · Hum Vaccin Immunother 2026
- Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis.
Qiu Z, Wang G, Lou Y, et al. · Front Pharmacol 2026
- First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.
Li Z, Zhu J, Ma K · Expert Rev Pharmacoecon Outcomes Res 2026
- Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15.
Kerwash E, Butler AS, Malamatari M, et al. · Clin Transl Sci 2026
- Sugemalimab for Post-PD-1 Progression in Non-small Cell Lung Cancer.
Xu L, Pu X, Wang Q, et al. · J Immunother 2026
- Immunotherapy combined with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 expression levels.
Yi W, Muhetaer K, Chen L, et al. · BMC Cancer 2026
Also in development for NSCLC (Non-small Cell Lung Cancer)
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- JMKX001899Phase 31 trial
Jemincare · NSCLC (Non-small Cell Lung Cancer)
- IAM1363Phase 21 trial
Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer
- OSE-279Phase 21 trial
OSE Immunotherapeutics · Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
- TXN10128Phase 21 trial
Txinno Bioscience Inc. · NSCLC (Non-small Cell Lung Cancer)
- YH42946Phase 21 trial
Yuhan Corporation · NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.